Full Press Release Details
Update on ongoing Dupixent (dupilumab)
chronic spontaneous urticaria Phase 3 program
PARIS and TARRYTOWN, N.Y., February 18, 2022. A Phase 3 trial (CUPID STUDY B)
evaluating Dupixent (dupilumab) in patients with chronic spontaneous urticaria (CSU), who were refractory to omalizumab, will stop due to futility based on a
pre-specified interim analysis. Although positive numerical trends in reducing itch and hives were observed, the results from the interim analysis did not demonstrate statistical significance for the primary
endpoints. The analysis was conducted by an independent interim analysis review committee. In the trial, patients who were refractory to omalizumab treatment and uncontrolled on antihistamines received Dupixent plus standard of care compared to
standard of care alone for 24 weeks. The safety data were generally consistent with the known safety profile of Dupixent in its approved indications.
The LIBERTY-CUPID pivotal program was initiated in 2020 with an accelerated
direct-to-Phase 3 strategy. The previously reported Phase 3
trial, which evaluated a different group of patients who were biologic-na ve, met its primary and all key secondary endpoints at 24 weeks showing that adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives compared to antihistamines alone. The companies remain committed to advancing Dupixent for patients with CSU uncontrolled on antihistamines
and are evaluating next steps.
John Reed, M.D., Ph.D.
Executive Vice President, Global Head of Research and Development at Sanofi
Although we are disappointed in these latest results, this interim analysis contributes to furthering our
understanding of the role of type 2 inflammation in this subset of CSU patients who are refractory to all other approved therapies. Based on the results seen in our first Phase 3 trial, and the numerical trends observed in this interim analysis, we
remain committed to advancing Dupixent as an option for patients suffering from CSU who are uncontrolled on anti-histamines. We look forward to discussing next steps with regulators.
Detailed results from the first trial will be presented at the AAAAI Annual Meeting later this month and the companies expect to share results from the
second trial in a scientific forum. Sanofi and Regeneron are rapidly advancing a broad clinical development program to evaluate Dupixent in diseases with significant unmet need and where type 2 inflammation may play a role. The companies also
recently announced positive Phase 3 results in eosinophilic esophagitis (EoE) and prurigo nodularis (PN), and additional results are also expected later this year in pediatric EoE, chronic inducible urticaria-cold (CindU), and hand and foot atopic
The potential use of Dupixent in CSU, EoE, PN, CindU and hand and foot atopic dermatitis are currently
under clinical development and the safety and efficacy have not been fully evaluated by any regulatory authority.
Spontaneous Urticaria
CSU is a chronic inflammatory skin disease characterized by the sudden onset of hives on the skin and/or swelling
deep under the skin. Despite standard-of-care treatment, people with CSU often experience symptoms including a persistent itch or burning sensation, which can be
debilitating and significantly impact quality of life. Swelling often occurs on the face, hands and feet, but can also affect the throat and upper airways.
About the Dupixent Phase 3 Program in CSU (LIBERTY-CUPID)
Study B of the Phase 3 randomized, double-blind, placebo-controlled LIBERTY-CUPID clinical program evaluated the efficacy and safety of Dupixent in 83
patients with CSU aged 12 to 80 years who remained symptomatic despite standard-of-care treatment and were intolerant or incomplete responders to omalizumab. During the 24-week treatment period, patients received Dupixent, or placebo every two weeks added to standard-of-care antihistamines.
The primary endpoints assessed the change from baseline in itch (measured by the weekly itch severity score) and the change from baseline in itch and
hives (measured by the weekly urticaria activity score) at 24 weeks.
Study A of clinical program evaluated the efficacy and safety of Dupixent as
an add-on therapy to standard-of-care antihistamines compared to antihistamines alone in 138 patients aged 6 years and older with
CSU who remained symptomatic despite antihistamine use and were not previously treated with omalizumab.
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rinusinusitis with nasal polyps (CRSwNP).
Dupixent is currently approved in the U.S., Europe, Japan and other countries around the world for use in specific patients with moderate-to-severe atopic dermatitis, as well as certain patients with asthma or CRSwNP in different age populations. Dupixent is also approved in one or more of these
indications in more than 60 countries around the world and more than 350,000 patients have been treated globally.
Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date,
dupilumab has been studied across 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2
inflammation or other allergic processes including chronic spontaneous urticaria (Phase 3), chronic inducible urticaria-cold (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), prurigo nodularis (Phase 3), eosinophilic
esophagitis (Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase 3), bullous pemphigoid (Phase 3), chronic rhinosinusitis without nasal polyposis (Phase 3), allergic fungal rhinosinusitis (Phase 3), allergic
bronchopulmonary aspergillosis (Phase 3) and peanut allergy (Phase 2). These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led
for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in
development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our
proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics
Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people s lives.
Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of
people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Sanofi Media Relations
Sally Bain | + 1 617 834 6026 | sally.bain@sanofi.com
Sanofi Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
Arnaud Del pine | + 33 06 73 69 36 93 |
Driancourt | + 33 06 40 56 92 | corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Priya Nanduri | priya.nanduri@sanofi.com
Nathalie Pham | + 33 07 85 93 30 17 |
Regeneron Media Relations
Hannah Kwagh | + 1 914 847 6314 |
Regeneron Investor Relations
Vesna Tosic | + 914 847 5443 |
Sanofi Disclaimers or Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking
statements are generally identified by the words expects , anticipates , believes , intends , estimates , plans and similar expressions. Although Sanofi s management believes
that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include
among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties
inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks
associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that COVID-19 will have on us,
our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19
on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also
include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in
Sanofi s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking
information or statements.
Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance
of Regeneron Pharmaceuticals, Inc. ( Regeneron or the Company ), and actual events or results may differ materially from these forward-looking statements. Words such as anticipate, expect,
intend, plan, believe, seek, estimate, variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking
statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that
has caused the COVID-19 pandemic) on Regeneron s business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron s and its collaborators
ability to continue to conduct research and clinical programs, Regeneron s ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively,
Regeneron s Products ), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron s Products and product candidates being developed by Regeneron and/or its collaborators or
licensees (collectively, Regeneron s Product Candidates ) and research and clinical programs now underway or planned, including without limitation Dupixent (dupilumab) for the
treatment of chronic spontaneous urticaria ( CSU ); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees, such as the LIBERTY-CUPID clinical program
(including Study A of the program, results of which were previously reported), may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of
the utilization, market acceptance, and commercial success of Regeneron s Products (such as Dupixent) and Regeneron s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or
voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron s Products (such as Dupixent for the treatment of CSU) and Regeneron s Product
Candidates; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron s Product Candidates and new indications for Regeneron s Products, such as Dupixent for the treatment of CSU,